Cystoid macular retinal degeneration

disease
On this page

Also known as cystoid macular degeneration of retina

Summary

Cystoid macular retinal degeneration (MONDO:0001919) is a disease. A subtype of degeneration of macula and posterior pole — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecystoid macular retinal degeneration
Mondo IDMONDO:0001919
DOIDDOID:14245
SNOMED CT14046000
UMLSC0154850
MedGen472900
Is cancer (heuristic)no

Also known as: cystoid macular degeneration of retina

Disease family

This is a subtype of degeneration of macula and posterior pole. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationmacular degenerationdegeneration of macula and posterior polecystoid macular retinal degeneration

Related subtypes (5): hole retinal cyst, preretinal fibrosis, toxic maculopathy, age-related macular degeneration, retinal drusen

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.